Showing 56-60 of 84 clinical outcomes & condition measurement and management:
OM1 Launches Multiple Sclerosis Registry With More Than 20,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, July 14, 2021 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its multiple sclerosis (MS) registry. MS is an auto-immune, inflammatory disease that attacks the central nervous system (CNS) and causes a variety of neurological symptoms, such as muscle weakness, spasticity, fatigue, numbness, vision[…]

CNS & Behavioral Health: Using RWD to Accelerate Research & Improve Outcomes

Tue, Jun 22, 2021 2:00 PM – 3:00 PM EDT Register >> Nearly 20% of Americans are diagnosed with a mental health condition every year. Yet, more than half of those don’t receive a treatment for their condition. Globally, neurological disorders are one of the leading causes of disability and death with few if any[…]

OM1 Rheumatoid Arthritis Registry Reaches More Than 200,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, April 20, 2021 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, announced its Rheumatoid Arthritis (RA) registry now includes longitudinal clinical data from rheumatology specialists on more than 200,000 patients. OM1 also offers other specialty rheumatology registries, including Juvenile Idiopathic Arthritis (JIA), which has deep[…]

American Academy Of Dermatology Collaborates With OM1 To Empower More Measured & Precise Care And Treatments For Dermatology

BOSTON, April 8, 2021 /PRNewswire/ — OM1, a real-world outcomes and technology company, today announced a strategic collaboration with the American Academy of Dermatology (AAD) connecting the Academy’s DataDerm™ clinical data registry to OM1’s real-world data and evidence platforms. The AAD estimates that 1 in 4 Americans (more than 85 million) see a physician for[…]

1 … 10 11 12 13 14 … 17